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Nashville, TennesseeObjectives This study sought to examine the contemporary incidence, predictors and outcomes of
acute kidney injury in patients undergoing percutaneous coronary interventions.
Background Acute kidney injury (AKI) is a serious and potentially preventable complication of
percutaneous coronary interventions (PCIs) that is associated with adverse outcomes. The
contemporary incidence, predictors, and outcomes of AKI are not well deﬁned, and clarifying these
can help identify high-risk patients for proactive prevention.
Methods A total of 985,737 consecutive patients underwent PCIs at 1,253 sites participating in the
National Cardiovascular Data Registry Cath-PCI registry from June 2009 through June 2011. AKI was
deﬁned on the basis of changes in serum creatinine level in the hospital according to the Acute Kidney
Injury Network (AKIN) criteria. Using multivariable regression analyses with generalized estimating
equations, we identiﬁed patient characteristics associated with AKI.
Results Overall, 69,658 (7.1%) patients experienced AKI, with 3,005 (0.3%) requiring new dialysis.
On multivariable analyses, the factors most strongly associated with development of AKI included
ST-segment elevation myocardial infarction (STEMI) presentation (odds ratio [OR]: 2.60; 95% conﬁdence
interval [CI]: 2.53 to 2.67), severe chronic kidney disease (OR: 3.59; 95% CI: 3.47 to 3.71), and cardiogenic
shock (OR: 2.92; 95%CI: 2.80 to 3.04). The in-hospitalmortality ratewas 9.7% for patientswith AKI and34%
for those requiring dialysis compared with 0.5% for patients without AKI (p< 0.001). After multivariable
adjustment, AKI (OR: 7.8; 95%CI: 7.4 to 8.1, p< 0.001) anddialysis (OR: 21.7; 95%CI: 19.6 to 24.1; p< 0.001)
remained independent predictors of in-hospital mortality.
Conclusions Approximately 7% of patients undergoing a PCI experience AKI, which is strongly
associated with in-hospital mortality. Deﬁning strategies to minimize the risk of AKI in patients
undergoing PCI are needed to improve the safety and outcomes of the procedure.
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2Acute kidney injury (AKI) after a percutaneous coronary
intervention (PCI) is a common and serious complication
of the procedure and is associated with an increased risk of
myocardial infarction (MI), dialysis, and death (1–17). Even
small increases in serum creatinine have been associated with
increased hospital length of stay and excess costs (18–22).
Accordingly, multiple stakeholders have emphasized AKI
prediction and prevention as a major healthcare priority
because therapeutic options are limited once AKI develops.
Despite its importance, the reported incidence of AKI
after PCI varies widely, from 3% to 19%. This wide variation
is thought to be a consequence of estimates from single-
center studies or studies that preceded the current use
of volume expansion protocols and iso-osmolar contrast
agents. Furthermore, previous studies have used varyingVA, Nashville, Tennessee; and the yyV
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infarctiondeﬁnitions of AKI, making it
difﬁcult to compare AKI rates
across different studies and pop-
ulations. Deﬁning the prevalence
and consequences of AKI in
a large national sample of centers
is critically important for identi-
fying the value of national efforts
to address AKI as a potential
quality metric. Recently, there
has been widespread adoption by
the nephrology and critical care
communities of the Acute
Kidney Injury Network (AKIN)
criteria to provide uniform stan-
dards for the deﬁnition and
classiﬁcation of AKI (23). These
parameters updated the original
RIFLE criteria to be readily
obtainable worldwide and broad
enough to accommodate varia-
tions in clinical presentations
among different age groups,
locations, and clinical settings(24,25). The AKIN criteria have also recently been
embraced by the cardiology community and are used in most
current studies of AKI in the cardiology literature (26–28).anderbilt University Medical Center, Nashville,
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accepted June 6, 2013.Better deﬁning the current incidence and predictors
of AKI using the AKIN criteria in a large, real-word registry
of patients undergoing PCI and its impact on clinical
outcomes can provide a context for addressing this compli-
cation and serve as a stimulus to improve prevention efforts.
Using the National Cardiovascular Data Registry (NCDR),
the world’s largest PCI registry, we evaluated the incidence
of AKI using the AKIN criteria and examined the patient
factors associated with AKI and the association of AKI with
in-hospital morbidity and mortality.
Methods
Study population. The NCDR Cath-PCI registry, co-
sponsored by the American College of Cardiology (ACC)
and the Society for Cardiovascular Angiography and Inter-
ventions, has been previously described (29,30). The registry
collects data on patient and hospital characteristics, clinical
presentation, treatments, and outcomes associated with
PCIs from >1,200 U.S. hospitals. The data are entered into
ACC-certiﬁed software at participating institutions. There
is a comprehensive data quality program, including both data
quality report speciﬁcations for data capture and trans-
mission and an auditing program. The data collected are
exported in a standard format to the ACC Heart House
(Washington, DC). The complete deﬁnitions of all variables
were prospectively deﬁned by a committee of the ACC and
are available at the ACC NCDR Website.
For this study, we identiﬁed all patients undergoing a PCI
between June 1, 2009, and June 30, 2011, enrolled in the
NCDR (N ¼ 1,254,089). We excluded patients without
a pre-procedure and a peak post-procedure in-hospital serum
creatinine level (n ¼ 239,025; 19%), patients undergoing
multiple PCIs during a single hospitalization (n ¼ 32,999;
2.6%), and patients currently on dialysis at the time of their
PCI (n ¼ 24,517; 2%). The ﬁnal analytical cohort included
957,548 patients undergoing PCI (Fig. 1).
Baseline kidney function. Using the pre-procedure serum
creatinine level as baseline, we calculated the estimated glo-
merular ﬁltration rate (eGFR) (in ml/min/1.73 m2) using the
Modiﬁcation of Diet in Renal Disease equation and classiﬁed
patients as having normal baseline renal function (eGFR,>60),
mild chronic kidney disease (CKD) (eGFR, 45 to 60), mode-
rate CKD (eGFR, 30 to 45), or severe CKD (eGFR,<30).
Primary outcomes: AKI and AKI requiring dialysis. The
primary outcome was AKI, using the change from pre-
procedure to peak serum creatinine levels. We classiﬁed
AKI using the AKIN criteria (AKI stage 1, 0.3 mg/dl
absolute or 1.5 to 2.0-fold relative increase in serum creati-
nine; AKI stage 2,>2- to 3-fold increase in serum creatinine;
AKI stage 3, >3-fold increase in serum creatinine or serum
creatinine>4.0 mg/dl with an acute increase of>0.5 mg/dl).
AKI requiring dialysis (AKI-D) was an in-hospital outcome
identiﬁed using a pre-deﬁned NCDR data element for acute
Figure 1. Population Selection Flow Diagram
Initial cohort and cohort exclusions. EX ¼ exclusion; PCI ¼ percutaneous
coronary intervention.
Figure 2. Incidence of Acute Kidney Injury or Dialysis
The incidence of acute kidney injury as deﬁned by the Acute Kidney Injury
Network (AKIN) deﬁnitions. AKIN 1, 0.3 mg/dl absolute or 1.5- to 2.0-fold
relative increase in serum creatinine; AKIN 2, >2- to 3-fold increase in serum
creatinine; AKIN 3, >3-fold increase in serum creatinine or serum creatinine
>4.0 mg/dl with an acute increase of >0.5 mg/dl. Dialysis was an in-hospital
outcome identiﬁed using a pre-deﬁned National Cardiovascular Data Registry
data element for acute or worsening renal failure, necessitating new renal
dialysis.
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3or worsening renal failure necessitating new renal dialysis.
Patients with AKI-D were included in the AKI group but
were also examined separately to identify independent
predictors of the occurrence of the need for dialysis.
Secondary outcomes: clinical endpoints. Secondary outcomes
of the study, used to establish the clinical importance of AKI,
were the following: 1) in-hospital major bleeding, deﬁned as
a 3-g/dl decrease in hemoglobin, transfusion of whole
packed red blood cells, or an intervention to stop the bleeding
within 72 h of the procedure; 2) in-hospital MI, deﬁned as an
increase in serum troponin or creatine kinase (or whatever the
speciﬁc biomarkers were) >3 times the upper limit of normal
within 24 h post-PCI or, in patients with elevated baseline
cardiac biomarkers, a characteristic increase and decrease in
cardiac biomarkers; and 3) in-hospital mortality.
Statistical analysis. Patients were stratiﬁed by the absence
of AKI; AKI stages 1, 2, and 3, or AKI-D after PCI.
Differences between groups were compared using chi-square
tests for categorical variables and the Wilcoxon rank sum or
Kruskal-Wallis test for continuous variables.
We considered important baseline patient characteristics
and clinically relevant variables for inclusion in models
examining risk factors for AKI or AKI-D. Candidate variables
included age, sex, body mass index, intra-aortic balloon pumpinsertion before the procedure, congestive heart failure (CHF)
on presentation, diabetes, hypertension, previousMI, previous
PCI, previous coronary artery bypass grafting, previous cere-
brovascular disease, previous peripheral arterial disease, chronic
lung disease, unstable angina/non–ST-segment elevation
myocardial infarction (STEMI), STEMI, shock on presen-
tation, cardiac arrest on presentation, anemia (hemoglobin
<10 mg/dl), contrast dose in 75-ml increments, multiple
procedures, and patients transferred from an outside hospital.
Logistic regression with the generalized estimating equation
method was used to account for within-hospital clustering.
To assess the association between AKI or AKI-D and in-
hospital major bleeding, MI, and death, we used multivar-
iable analyses with generalized estimating equation to adjust
for associations clustered within hospitals. The NCDR PCI
mortality model variables (31) were used for risk-adjusting
MI and death and included age, race, sex, body mass index,
previous congestive heart failure, previous valve surgery,
previous cerebrovascular disease, peripheral vascular disease,
chronic lung disease, previous PCI, diabetes, admission
symptom presentation, cardiogenic shock, pre-operative
intra-aortic balloon pump, ejection fraction, New York
Heart Association functional class, coronary lesion >50%,
highest pre-procedure Thrombolysis In Myocardial Infarc-
tion ﬂow, and PCI status (elective, urgent, emergent,
salvage). For the major bleeding endpoint, the validated
NCDR bleeding model was used for risk adjustment, which
included age, sex, previous heart failure, GFR, peripheral
vascular disease, no previous PCI, NYHA/Canadian
Cardiovascular Society functional class IV heart failure,
STEMI, non-STEMI, and cardiogenic shock (32).
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4Results
Baseline characteristics. Of the 985,737 patients in our
cohort, AKI developed in 69,658 patients (7.1%): 56,850
(6%) with AKI stage 1, 4,534 (0.5%) with AKI stage 2,
2,441 (0.3%) with AKI stage 3, and 3,005 (0.3%) with
AKI-D (Fig. 2). The mean  SD age was 64.8  12.2
years (Table 1), and the patients had a high prevalence of
comorbidities including diabetes (35.8%), dyslipidemia
(79.9%), and hypertension (81.7%). The majority ofTable 1. Baseline Characteristics of the Study Cohort
Variable
Total
(N ¼ 954,729)
No AKI
(n ¼ 888,023, 93.0%)
AKI S
(n ¼ 56,8
Patient characteristics
Age, yrs 64.8  12.2 64.6  12.1 68.2 
Female 313,445 (32.8) 287,161 (32.3) 22,077 (
Nonwhite race 109,851 (11.5) 99435 (11.2) 8,304 (
Previous MI 284,579 (29.8) 263,024 (29.6) 18,467 (
Previous CHF 110,668 (11.6) 95,557 (10.8) 12,535 (
Diabetes 341,934 (35.8) 309,073 (34.8) 27,543 (
CVD 116,718 (12.2) 104,418 (11.8) 10,406 (
PVD 116,948 (12.3) 104,669 (11.8) 10,273 (
CLD 145,238 (15.2) 131,608 (14.8) 11,481 (
Hypertension 780,800 (81.8) 723,062 (81.5) 49,339 (
Active tobacco use 266,111 (27.9) 250,361 (28.2) 13,358 (
Dyslipidemia 763,101 (80.0) 711,301 (80.2) 44,491 (
Previous PCI 379,592 (39.8) 355,352 (40.0) 21,051 (
Previous CABG 177,449 (18.6) 163,298 (18.4) 12,229 (
Baseline CKD, ml/min/1.73 m2
Normal
(eGFR 60)
675,826 (70.8) 641,025 (72.2) 30,307 (
Mild
(eGFR 45–60)
163,272 (17.1) 150,219 (16.9) 11,193 (
Moderate
(eGFR 30–45)
87,491 (9.2) 76,198 (8.6) 9,537 (
Severe
(eGFR<30)
27,980 (2.9) 20,581 (2.3) 5,813 (
Presentation and
hospital care
No symptoms 90,281 (9.5) 85,244 (9.6) 4,406 (
Atypical chest pain
Stable angina 159,547 (16.7) 153,399 (17.3) 5,581 (
ACS: unstable angina 347,775 (36.4) 328,505 (37.0) 17,185 (
ACS: non-STEMI 179,191 (18.8) 161,075 (18.1) 15,237 (
ACS: STEMI 149,753 (15.7) 133,341 (15.0) 12,919 (
CHF 96,214 (10.1) 79,536 (9.0) 13,340 (
Cardiogenic shock 17,622 (1.8) 11,746 (1.3) 3,987 (
Cardiac arrest 17,357 (1.8) 13,378 (1.5) 2,802 (
IABP 0 0
Length of stay, days 2.2  4.4 2.0  3.9 4.8 
Contrast volume, ml 185 (140–250) 185 (140–245) 190 (
Values are mean  SD, n (%), or median (interquartile range).
ACS ¼ acute coronary syndrome; AKI ¼ acute kidney injury; CABG ¼ coronary artery bypass grafti
CVD ¼ cardiovascular disease; eGFR ¼ estimated glomerular ﬁltration rate; IABP ¼ intra-aortic balloon p
elevation myocardial infarction.patients (71.2%) presented with acute coronary syndromes.
Almost 30% of patients had CKD at baseline (eGFR
60 ml/min/1.73 m2), the mean  SD length of stay was
2.2  4.4 days, and the median volume of contrast used
was 185 ml (interquartile range: 140 to 250 ml).
Patients with AKI or AKI-D were signiﬁcantly older than
patients without AKI and were more likely to have had
a history of anemia, MI, congestive heart failure, and
coronary artery bypass grafting (Table 1). Patients with AKI
and AKI-D were also more likely to have had a history oftage 1
50, 6.0%)
AKI Stage 2
(n ¼ 4,534, 0.5%)
AKI Stage 3
(n ¼ 2,441, 0.3%)
Dialysis
(n ¼ 2,881, 0.3%) p Value
12.5 69.1  12.5 66.6  12.4 68.8  12.0 <0.001
38.8) 2,079 (45.9) 1,008 (41.3) 1,120 (38.9) <0.001
14.6) 616 (13.6) 354 (14.5) 463 (16.1) <0.001
32.5) 1,407 (31.1) 741 (30.4) 940 (32.7) 0.002
22.1) 1,156 (25.5) 444 (18.2) 976 (33.9) <0.001
48.5) 2,339 (51.6) 1,189 (48.7) 1,790 (62.2) <0.001
18.3) 883 (19.5) 410 (16.8) 601 (20.9) <0.001
18.1) 907 (20.0) 419 (17.2) 680 (23.6) <0.001
20.2) 1,041 (23.0) 453 (18.6) 655 (22.7) <0.001
86.8) 3,877 (85.6) 2,027 (83.1) 2,495 (86.7) <0.001
23.5) 1,107 (24.5) 676 (27.8) 609 (21.2) <0.001
78.4) 3,354 (74.2) 1,833 (75.2) 2,122 (73.8) <0.001
37.0) 1,453 (32.1) 830 (34.0) 906 (31.5) <0.001
21.5) 877 (19.3) 417 (17.1) 628 (21.8) <0.001
53.3) 2,375 (52.4) 1,634 (66.9) 485 (17.8) <0.001
19.7) 1,013 (22.3) 427 (17.5) 420 (15.4) <0.001
16.8) 850 (18.7) 266 (10.9) 640 (23.5) <0.001
10.2) 296 (6.5) 114 (4.7) 1,176 (43.2) <0.001
7.8) 271 (6.0) 176 (7.2) 184 (6.4) <0.001
9.8) 267 (5.9) 197 (8.1) 103 (3.6) <0.001
30.2) 975 (21.5) 597 (24.5) 513 (17.8) <0.001
26.8) 1,316 (29.0) 629 (25.8) 934 (32.4) <0.001
22.7) 1,613 (35.6) 794 (32.5) 1,086 (37.7) <0.001
23.5) 1,479 (32.7) 616 (25.2) 1,243 (43.2) <0.001
7.0) 775 (17.1) 369 (15.1) 745 (25.9) <0.001
4.9) 519 (11.4) 268 (11.0) 390 (13.5) <0.001
0 0 0 0 0
6.2 8.6  9.4 8.3  14.3 15.0  17.9 <0.001
140–250) 200 (150–275) 200 (150–275) 200 (135–260) <0.001
ng; CHF ¼ congestive heart failure; CKD ¼ chronic kidney disease; CLD ¼ chronic lung disease;
ump; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment
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5cardiovascular disease and peripheral artery disease and to
present with non-STEMI or STEMI compared with
patients without AKI.
Incidence of AKI and AKI-D in patients with CKD. The inci-
dence of AKI and AKI-D after PCI was strongly related to
the severity of baseline CKD and STEMI presentation
(Fig. 3). With increasing severity of baseline CKD, the
incidence of AKI and AKI-D increased signiﬁcantly. For
example, the risk of AKI and AKI-D in patients with normal
baseline renal function was 5.2% and 0.07%, respectively,
compared with 26.6% and 4.3%, respectively, in patients
with severe CKD at baseline (eGFR <30 ml/min/1.73 m2).
Patients with severe CKD at baseline presenting with
STEMI represented the highest-risk subgroup, with an AKI
incidence of 36.9% and an AKI-D incidence of 7.2%.Figure 3. Incidence of AKI or Dialysis Stratiﬁed by Severity of
Chronic Kidney Disease
(A) AKI and dialysis by GFR level: all patients. (B) AKI and dialysis by GFR level:
ST-segment elevation myocardial infarction (STEMI) patients. The incidence of
AKI on the left y-axis and dialysis on the right y-axis stratiﬁed by baseline
chronic kidney disease as deﬁned by a patient’s GFR. GFR was calculated using
the Modiﬁcation of Diet in Renal Disease equation on the basis of the patient’s
pre-procedure serum creatinine level. (A) All patients. (B) Only patients
presenting with STEMI. AKI ¼ acute kidney injury; AKIN ¼ Acute Kidney Injury
Network; GFR ¼ glomerular ﬁltration rate; STEMI ¼ ST-segment elevation
myocardial infarction.Independent predictors of AKI and AKI-D after PCI. Inde-
pendent factors associated with AKI or AKI-D are shown in
Figure 4. Among these factors, severe baseline CKD (odds
ratio [OR]: 3.59; 95% conﬁdence interval [CI]: 3.47 to
3.71), cardiogenic shock (OR: 2.92; 95% CI: 2.80 to 3.04),
and STEMI presentation (OR: 2.60; 95% CI: 2.53 to 2.67)
were associated with the greatest risk of AKI. Similarly,
severe CKD (OR: 28.54; 95% CI: 25.54 to 31.96) and
moderate CKD (OR: 5.47; 95% CI: 5.09 to 6.47) were also
associated with the greatest risk of AKI-D.Figure 4. Independent Predictors of AKI or Dialysis
(A) Independent predictors of any AKI (including dialysis). (B) Independent
predictors of dialysis only. Odds ratios were calculated using logistic regres-
sion with generalized estimating equation methods. ACS ¼ acute coronary
syndrome; CVD ¼ cerebrovascular disease; DM ¼ diabetes mellitus; HF ¼ heart
failure; IABP ¼ intra-aortic balloon pump; NSTEMI/UA ¼ non–ST-segment
elevation myocardial infarction/unstable angina; other abbreviations as in
Figure 3.
Figure 5. Risk of Death, Bleeding, and Myocardial Infarction in Patients
With AKI and/or Dialysis
The incidence of death, bleeding, and MI stratiﬁed by the absence and
presence of AKI and the presence of dialysis. MI ¼myocardial infarction; other
abbreviations as in Figure 3.
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6Association of AKI with adverse clinical endpoints. Of the
69,658 patients in whom AKI developed after PCI, the in-
hospital rates of MI, bleeding, and death was 3.8%, 6.4%,
and 9.6% respectively, compared with 2.1%, 1.4%, and
0.5%, respectively, in patients in whom AKI did not
develop. The rates of MI (7.9%), bleeding (15.8%), and
death (34.3%) were the highest in the 3,005 patients in
whom AKI-D developed (Fig. 5). When stratiﬁed by AKI
severity, patients with AKI stages 2 and 3 had similar rates
of death, bleeding, and MI (Table 2).
Even after adjusting for differences in baseline patient
characteristics, AKI was associated with a signiﬁcantly
increased odds of bleeding (OR: 2.38; 95% CI: 2.27 to
2.49), MI (OR: 1.66; 95% CI: 1.58 to 1.75), and death
(OR: 3.68; 95% CI: 3.49 to 3.88). Patients with AKI-D had
an even higher odds of bleeding (OR: 4.56; 95% CI: 4.12 to
5.05), MI (OR: 2.70; 95% CI: 2.35 to 3.12), and death
(OR: 4.56; 95% CI: 4.12 to 5.05). When stratiﬁed by AKI
stages, all stages were independently associated with
bleeding, MI, or death (Fig. 6).
Discussion
In this large, contemporary, real-world study evaluating
patients undergoing PCI, we found that AKI developedTable 2. Incidence of Death, Bleeding, and MI Stratiﬁed by
AKIN Stages of AKI
AKIN Stage Death, % Bleeding, % MI, %
NO AKI 0.5 1.4 2.1
1 6.6 5.4 3.3
2 24.6 11.4 5.9
3 23.4 9.5 5.7
AKIN ¼ Acute Kidney Injury Network; other abbreviations as in Table 1.in 7.1% of patients, of whom 0.3% required dialysis.
Pre-procedure characteristics such as STEMI presentation
and baseline CKD were powerful predictors of AKI and
AKI-D, increasing the odds by 2- to 28-fold. In risk-
adjusted analyses, AKI and AKI-D were independently
associated with markedly increased risks of in-hospital major
bleeding, MI, and death. Our study conﬁrmed a high
in-hospital mortality rate in patients with AKI (9.6%) or
AKI-D (34.3%) compared with patients not experiencing
AKI (0.5%) or AKI-D (1.1%). Collectively, these data
demonstrate that AKI is common and independently asso-
ciated with other adverse events and would justify a national
effort to improve prevention as a foundation for greater
safety and better PCI outcomes.
The results of our study highlight the ongoing problem
of 2AKI in post-PCI patients, despite increased physician
awareness and measures to prevent AKI in this setting (26).
Previous studies that evaluated the incidence of AKI after
PCI have reported incidence rates ranging from as low
as 0.7% to upward of 19% (1,2,5,6,9,10,15,16). However,
most of these studies were single-center registries from more
than a decade ago, and many used disparate deﬁnitions of
AKI. Furthermore, in 2007, new national guidelines rec-
ommended AKI prevention strategies in patients under-
going coronary angiography, including volume expansion
and low or iso-osmolar contrast agents; thus, older studies
may not represent current practice (33). Our study, which
included PCIs conducted between 2009 and 2011, is more
likely to reﬂect current practices with regard to AKI
reduction strategies and more accurately represent current
AKI incidence rates and in-hospital outcomes.
To address the absence of a universal deﬁnition of AKI,
international experts formed the AKIN (23) and developed
the AKIN criteria for AKI to reﬂect the clinical signiﬁcance
of relatively small increases in serum creatinine and to enable
future comparisons of the incidence, outcomes, and efﬁcacy
of therapeutic interventions for AKI (18,34,35). This stan-
dardized deﬁnition of AKI has been embraced by the
nephrology and critical care community over the past 5 years
and is now the predominant deﬁnition used by the cardi-
ology community. For example, the Valve Academic
Research Consortium, charged with proposing standardized
consensus deﬁnitions for important clinical endpoints in
future trials and registries of transcatheter aortic valve
implantation, chose the AKIN criteria deﬁnition of AKI to
capture this signiﬁcant clinical endpoint. This consensus
deﬁnition of AKI of transcatheter aortic valve implantation
will allow comparison AKI rates across procedures (36,37).
To our knowledge, this is the ﬁrst study to use the
AKIN deﬁnition of AKI to describe the current incidence
of AKI in a large cohort of post-PCI patients. Our study
extends the recent report by James et al. (38), which
described the incidence of AKI using AKIN criteria in
a Canadian cohort undergoing coronary angiography. Of
Figure 6. Independent Predictors of Bleeding, MI, and Death
(A) Independent predictors of death. (B) Independent predictors of major bleeding. (C) Independent predictors of myocardial infarction. Odds ratios were calculated
using logistic regression with generalized estimating equation methods. Card Shock ¼ cardiogenic shock; CHF ¼ congestive heart failure; CLD ¼ chronic lung disease;
GFR - 10 ¼ every 10-unit decrease in glomerular ﬁltration rate; PVD ¼ peripheral vascular disease; NYHA ¼ New York Heart Association; other abbreviations as in
Figures 3 and 5.
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7the 14,782 participants in that study, AKI developed in
9.6%, which was a signiﬁcant risk factor for long-term
mortality, end-stage renal disease, and hospitalization
for cardiovascular and renal events. Our current AKI rates
post-PCI will enable meaningful comparison of future
studies across procedures and support quality improvement
programs and research.
The update to the PCI guidelines in 2011 added an
explicit statement that patients should be assessed for the
risk of AKI before PCI to more accurately educate patients
regarding the risks of the procedure and to considerAKI prevention strategies (39). Brown et al. (40) recently
showed that reported processes and clinical leadership in
AKI prevention protocols attributed to centers with lower
rates of AKI. Our approach, focusing on pre-procedure
variables to best estimate the periprocedure risk of AKI, can
enhance the patient consent process and risk/beneﬁt evalu-
ations. Importantly, the large size of our cohort allowed us to
also explore risk factors not only for AKI but also for AKI-
D, which is often difﬁcult to study given its low incidence,
but which is a particularly dreaded complication. For
example, in our study, patients with severe CKD (eGFR
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8<30 ml/min/1.73 m2) had 3-fold higher odds of AKI and
a 28-fold higher risk of AKI-D than patients with normal
renal function. Ongoing work to internally and externally
validate these models will eventually provide a bedside tool
for clinicians and their patients to better quantify the risks
of AKI and AKI-D in the near future.
Although AKI can occur in patients with an acute MI in
the absence of contrast exposure, our study focuses on patients
who are exposed to contrast during their PCI procedure
(26,41). Iodinated contrast has been hypothesized to cause
AKI via direct toxicity and hemodynamic changes and is the
third leading cause of AKI in hospitalized patients (42–44).
In accord with other studies, use of increasing volumes of
contrast is associated with an independently increased risk of
AKI and AKI-D in our population (2,5,16,45). Therefore,
our data suggest that using the minimal amount of contrast
dose to achieve optimal intraprocedural outcomes should be
emphasized with each case. Further studies in CathPCIR-
egistry evaluating the interaction between contrast dose,
clinical presentations, and baseline factors such as diabetes
and CKD are currently under way.
Our study also adds to the literature by validating the
morbid association between AKI and short-term in-hospital
bleeding, MI, and death in contemporary patients under-
going PCI. The most recent studies to evaluate the short-
term consequences of AKI after PCI were conducted more
than a decade ago as single-center studies and likely pre-
dated the use of routine hydration protocols and low osmolar
contrast agents (7,17). Nonetheless, after adjustment, AKI
remains strongly associated with 3- to 7-fold increased odds
of in-hospital MI, 2- to 5-fold increased odds of in-hospital
bleeding, and 3- to 11-fold increased odds of in-hospital
death. The link between AKI and these outcomes cannot be
established by the present study, but it conﬁrms that the
susceptibility to AKI is a marker for severe illness that may
share a common association with poor short-term outcomes.
Study limitations. First, patients and hospitals participating
in the NCDR may not be representative of all U.S. practice.
However, the CathPCI Registry represents >1,200 hospitals
across the United States and thus captures the majority of
PCI procedures nationally. Second, we used the in-hospital
pre-procedure creatinine level as the baseline value, which
may not have represented the patient’s true baseline serum
creatinine level. It is possible that clinically unstable patients
such as those patients presenting in heart failure or cardio-
genic shock may have had an increased pre-procedure serum
creatinine level. This would have underestimated the true
magnitude of the serum creatinine increase and biased our
results toward the null; however, we observed strong asso-
ciations of AKI with adverse clinical outcomes. Also, we were
unable to ascertain the timing of the peak serum creatinine
level, and therefore the association of the peak creatinine with
the PCI procedure could not be determined. Because the
creatinine level peaks 3 to 5 days after the procedure, we mayhave underestimated the true prevalence of AKI. However,
our ﬁnding of signiﬁcantly increased morbidity and mortality
with AKI using our deﬁnition suggests that we have iden-
tiﬁed a clinically important subset of patients with AKI.
Third, we did not have data on intravenous administration of
ﬂuid, concomitant use of renal toxic medications or poten-
tially renal protective medications, type of contrast media
used (e.g., iso-osmolar, low osmolar), or exposure to other
contrast procedures during the hospitalization. Finally,
although our multivariable models adjusted for a large
number of known predictors of AKI, the possibility of
unmeasured confounding cannot be eliminated.
Conclusions
In a large national cohort study of post-PCI patients, we
found that AKI developed in 7.1% of patients, 0.3%
of whom required acute dialysis. In risk-adjusted models,
clinical factors such as STEMI presentation and baseline
CKD markedly increased the risk of the development of
AKI or AKI-D. In addition, patients with AKI or AKI-D
in the hospital experienced very high rates of in-hospital
bleeding, MI, and death. By using standard criteria to deﬁne
AKI, our study can be compared with other clinical cohorts
and validates the use of such criteria for AKI as an inde-
pendent predictor of adverse events. Deﬁning more effective
strategies to minimize the risk of AKI in patients under-
going PCI is needed.Reprint requests and correspondence: Dr. Thomas T. Tsai,
Institute for Health Research, Kaiser Permanente Colorado,
University of Colorado Denver, 280 Exempla Circle, Lafayette,
Colorado 80026-3370. E-mail: thomas.tsai@coloradooutcomes.org.REFERENCES
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